データなし
データなし
Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.
Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And Wll Be Effective For Services Performed After Nov. 17
Iridex Comments on Changing Glaucoma Reimbursement Landscape
IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript Summary
IRIDEX Corp (IRIX) Q3 2024 Earnings Call Highlights: Strategic Moves and Glaucoma Growth Amid ...
このコンテンツを閲覧するにはログインが必要です。